Program
Pegloticase
Also written as “pegloticase”, “Pegloticase with MTX” and “Puricase”.
Its studies are mostly in Gout · Renal Insufficiency, Chronic, led by 3 companies.
Drug pagePegloticase: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 81 open or running | phase 4since Aug 9, 2018 | Aug 9, 2018 | Jun 18, 2028phase 3 · NCT07388498 |
| Savient Pharmaceuticals | 50 open or running | phase 3since May 10, 2006 | Mar 24, 2004 | none ahead |
| Ampel BioSolutionsits history only | 10 open or running | phase 2since Oct 30, 2015 | Oct 30, 2015 | none ahead |
Also a collaborator on its studies: IND 2 Results.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Savient Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2004First study: phase 2 study in GoutFirst studyNCT00080210 · 40 enrolled · United States
- May 10, 2006Phase 3 study in GoutNCT00325195 · 225 enrolled · United States, Canada, Mexico
- May 6, 2008Phase 3 study in GoutNCT00675103 · 7 enrolled · United States
- Oct 27, 2008Phase 3 study in GoutNCT01356498 · 151 enrolled · United States
- Nov 29, 2012Phase 1 study in Renal Insufficiency, ChronicNCT01739660 · 12 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 Savient Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01739660Renal Insufficiency, Chronic · United States | 1 | Completed | Apr 2013 | 12 |
| NCT01356498Gout · United States | 3 | Completed | Jan 2010 | 151 |
| NCT00675103Gout · United States | 3 | Completed | Jan 2009 | 7 |
| NCT00325195Gout · United States, Canada, Mexico | 3 | Completed | Oct 2007 | 225 |
| NCT00080210Gout · United States | 2 | Completed | 40 |
How it is read
Names in the registry
- “Pegloticase”, 9 entries
- “pegloticase”, 2 entries
- “Pegloticase with MTX”, 1 entry
- “Puricase”, 1 entry
- “pegloticase 8 mg i.v.”, 1 entry
Conditions, from the studies’ own filings
- Gout, 13 studies
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.